Research programme: HER2 receptor modulators - IBI-Lorenzini Istituto-Biochimico-Italiano-G-Lorenzini
Alternative Names: anti-HER2 humanized monoclonal antibodyLatest Information Update: 31 Oct 2021
Price :
$50 *
At a glance
- Originator Istituto Biochimico Italiano G Lorenzini
- Class Monoclonal antibodies
- Mechanism of Action ERBB 2 receptor modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for research development in Cancer in Germany (Parenteral)
- 28 Apr 2018 No recent reports of development identified for research development in Cancer in Italy (Parenteral)